Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
19 September 2022 | Story André Damons | Photo André Damons
Sithembiso Ndlovu
Sithembiso Ndlovu is a lecturer in the Dean’s Office, Faculty of Health Sciences who recently completed his research into the impact the COVID-19 pandemic had on gender-based violence (GBV) among women.

A lecturer at the University of the Free State (UFS) Faculty of Health Sciences hopes his research into the impact the COVID-19 pandemic had on gender-based violence (GBV) among women, could assist the victims and especially government and organisations to address this evil post-COVID-19. 

Sithembiso Ndlovu, a Public Health Lecturer in the Division of Public Health, Office of the Dean of Health Sciences, says this research was a narrative review paper which aimed to explore the impact of the COVID-19 pandemic on GBV among women since there is inadequate established literature on this topic, particularly in South Africa. The focus was on intimate partner violence.

He started working on the review in February 2021 and finished in August the same year where after the paper was published by the African Journal of Reproductive Health (AJRH) in July 2022. He says he believes his research aligns with the UFS narrative of creating opportunities and growth through leading, learning and teaching, focused research, and impactful engagement with society given the quality of the research that his review upholds. 

Looking at the state and impact of GBV

Says Ndlovu: “I believe my research will be impactful in academia and in the lives of women who experienced GBV during lockdown. The study will also be impactful to women who will experience GBV in the future through recommended interventions, which I believe government departments and various GBV-oriented organisations can adopt to curb the increase in GBV cases in the country post-COVID-19 pandemic. 

”All in all, the research expresses the notion of care for the well-being of South African women who are voiceless or powerless and thus creates an opportunity for them to be able to seek help.”

The researcher says he wanted to look at the state and impact of GBV among women during the pandemic in the South African context and lay a foundation for prospective interventions to mitigate the increase of GBV cases during the lockdown. He envisages government departments and local organisations that deal with issues relating to GBV to consider the proposed interventions. 

“Also, it remains vital to engage men on the importance of GBV and the role they can play in decreasing the prevalence of this second pandemic after the COVID-19 as President Cyril Ramaphosa noted,” says Ndlovu.

According to him, without proper and accessible support, there will always be an increased risk of victimisation, even in households where there was no violence before the lockdown. Multipronged and all-inclusive intervention strategies are needed to address the prevalence of GBV cases effectively and sufficiently in South Africa. 

What does the research show? 

Ndlovu says the research found that there are multiple factors that contributed to the surge in GBV cases in South Africa, including alcohol availability and consumption, job losses, financial dependence, psychological distress, and emotional imbalances during the lockdown. During the restrictive lockdown, women were more exposed to the aggressors at home, where varying hostile power dynamics prevail, leaving the victims with limited opportunity to find any potential help and support due to limited mobility.

“When I was drafting the paper, there was limited literature on GBV during COVID-19 and comparing and contrasting statistics between the two periods was challenging. At the start of lockdown in March 2020, 87 000 cases of GBV and interpersonal violence were reported, a significant increase compared to pre-COVID-19. 

“However, the reports did not specify the type of interpersonal violence, and GBV reported or the gender of the aggressor although it has been widely reported that male partners perpetrate most IPV.” 

Interventions

Ndlovu wrote in the research article that key intervention strategies in combating GBV and ensuring that victims are supported adequately include dialogues and interventions around high-level communication and behaviour change programmes, prioritisation of reported cases, and developing interventions tailored to respond to the economically vulnerable circumstances women encounter. 

“There should be an emergency strengthening of the support systems that could be utilised by women experiencing violence and who are planning to escape the violent environment during regulated lockdown curfew periods in South Africa.

“Interventions should also include denormalising violence against women by their male counterparts and men in general. This could be implemented through educational programmes in communities, including schools where violence is prevalent. In this regard, an evaluation study on a school violence programme in Tshwane found that the programme increased positive knowledge of violence and attitudes toward violence. The recommended services must also be offered in all South African official languages to ensure that information is received and understood extensively,” he wrote. 

GBV-related programmes need to be prioritised in every sector and government department. This would necessitate realistic measures and activities to ensure impact. Governments must collaborate with various organisations to derive interventions by eliminating factors contributing to a surge in GBV cases. 

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept